NorthStar Medical Radioisotopes has signed a nonexclusive letter of intent with GE Healthcare to supply GE with molybdenum-99 (Mo-99).
GE Healthcare will use the radioisotope to produce technetium-99m (Tc-99m), once NorthStar's nonuranium-based Mo-99 technology and RadioGenix isotope separation system have been approved by the U.S. Food and Drug Administration (FDA) and are available to market, NorthStar said.
NorthStar recently signed a similar agreement with the radiopharmacy chain Triad Isotopes.
